These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28838159)

  • 21. [The role of Sabin inactivated poliovirus vaccine in the final phase of global polio eradication].
    Dong SZ; Zhu WB
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Dec; 50(12):1032-1035. PubMed ID: 28057104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Introduction of Inactivated Poliovirus Vaccine and Impact on Vaccine-Associated Paralytic Poliomyelitis - Beijing, China, 2014-2016.
    Zhao D; Ma R; Zhou T; Yang F; Wu J; Sun H; Liu F; Lu L; Li X; Zuo S; Yao W; Yin J
    MMWR Morb Mortal Wkly Rep; 2017 Dec; 66(49):1357-1361. PubMed ID: 29240729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
    Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polio Eradication and Endgame Plan - Victory within Grasp.
    Patel M; Menning L; Bhatnagar P
    Indian Pediatr; 2016 Aug; 53 Suppl 1():S28-S32. PubMed ID: 27771636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global Polio Eradication,The Journey So Far.
    Thacker N; Yewale VN; Pathak A
    Indian Pediatr; 2016 Aug; 53 Suppl 1():S61-S64. PubMed ID: 27771642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Jan; 46(RR-3):1-25. PubMed ID: 9026708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost-effectiveness of alternative polio immunization policies in South Africa.
    Griffiths UK; Botham L; Schoub BD
    Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization.
    Khan MM; Sharma S; Tripathi B; Alvarez FP
    Public Health; 2017 Jan; 142():31-38. PubMed ID: 28057194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost analysis of post-polio certification immunization policies.
    Sangrujee N; Cáceres VM; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016.
    Immunization Systems Management Group of the Global Polio Eradication Initiative
    MMWR Morb Mortal Wkly Rep; 2015 Jul; 64(25):699-702. PubMed ID: 26135591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
    Duintjer Tebbens RJ; Thompson KM
    J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polio endgame: the global switch from tOPV to bOPV.
    Garon J; Seib K; Orenstein WA; Ramirez Gonzalez A; Chang Blanc D; Zaffran M; Patel M
    Expert Rev Vaccines; 2016 Jun; 15(6):693-708. PubMed ID: 26751187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A developing country perspective on vaccine-associated paralytic poliomyelitis.
    John TJ
    Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.
    Kalkowska DA; Thompson KM
    Risk Anal; 2021 Feb; 41(2):364-375. PubMed ID: 33590519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fractional-Dose Inactivated Poliovirus Vaccine Immunization Campaign - Telangana State, India, June 2016.
    Bahl S; Verma H; Bhatnagar P; Haldar P; Satapathy A; Kumar KN; Horton J; Estivariz CF; Anand A; Sutter R
    MMWR Morb Mortal Wkly Rep; 2016 Aug; 65(33):859-63. PubMed ID: 27559683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review.
    Bandyopadhyay AS; Modlin JF; Wenger J; Gast C
    Clin Infect Dis; 2018 Oct; 67(suppl_1):S35-S41. PubMed ID: 30376081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The polio endgame.
    Minor P
    Hum Vaccin Immunother; 2014; 10(7):2106-8. PubMed ID: 25608050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The challenge of changing the inactivated poliomyelitis vaccine in Latin America: declaration of the Latin American Society of Pediatric Infectious Diseases (SLIPE).
    Falleiros-Arlant LH; Avila-Agüero ML; Brea del Castillo J; Mariño C
    Rev Chilena Infectol; 2014 Oct; 31(5):590-603. PubMed ID: 25491459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remarks on the possibility of introducing the fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule.
    Arbo A; Falleiros-Arlant LH; López EL; Brea Del Castillo J; Martínez de Cuellar C; Moreno G; Rolón R; Cerda J; Eguiazú S;
    Rev Chilena Infectol; 2019 Feb; 36(1):83-90. PubMed ID: 31095207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.